Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer
This article was originally published here
The updated preliminary Phase 3 clinical data will serve as the basis for the anticipated initiation of the Company’s BLA submission in 4Q 2019 “After two very positive
The post Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!